Adjuvant Radiotherapy for Extrahepatic Cholangiocarcinoma: A Quality Assessment-Based Meta-Analysis
Conclusions: ART was shown to improve OS in all studies and in those selected for their reliable comparability.Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - August 26, 2021 Category: Cancer & Oncology Source Type: research

The Prognostic Impact of Tumor Differentiation on Recurrence and Survival after Resection of Hepatocellular Carcinoma Is Dependent on Tumor Size
Conclusions: Por HCC measuring ≥2 cm was associated with early recurrence. Hence, it had negative effects on OS. After surgery, patients with Por HCC measuring ≥5 cm should be cautiously monitored for early extrahepatic recurrence. These findings will help physicians devise treatment strategies for patients with HCC.Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - August 24, 2021 Category: Cancer & Oncology Source Type: research

Higher Enhancement Intrahepatic Nodules on the Hepatobiliary Phase of Gd-EOB-DTPA-Enhanced MRI as a Poor Responsive Marker of Anti-PD-1/PD-L1 Monotherapy for Unresectable Hepatocellular Carcinoma
Conclusion: The TTnP on HCC nodules with higher enhancement and the median PFS in patients who carried higher enhancement intrahepatic HCC nodules were significantly shorter than those in hypointense HCC nodules with anti-PD-1/PD-L1 monotherapy. The intensity of the nodule on the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI is a promising imaging biomarker for predicting unfavorable response with anti-PD-1/PD-L1 monotherapy in patients with HCC.Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - August 19, 2021 Category: Cancer & Oncology Source Type: research

Use of Antibiotics during Immune Checkpoint Inhibitor Treatment Is Associated with Lower Survival in Hepatocellular Carcinoma
Conclusions: Concurrent antibiotic use during immunotherapy was associated with higher mortality in patients with advanced HCC. Further studies should examine the role of gut dysbiosis on responses to ICI.Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - August 18, 2021 Category: Cancer & Oncology Source Type: research

Redefining Tumor Burden in Patients with Intermediate-Stage Hepatocellular Carcinoma: The Seven-Eleven Criteria
Conclusion: Conventional definitions of tumor burden were not optimal for patients with intermediate HCC. The new 7 –11 criteria had the best discriminative power in predicting radiologic response and survival in patients with intermediate-stage HCC undergoing TACE.Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - July 22, 2021 Category: Cancer & Oncology Source Type: research

APPLE News
Liver Cancer 2021;10:396 –398 (Source: Liver Cancer)
Source: Liver Cancer - July 20, 2021 Category: Cancer & Oncology Source Type: research

Twenty Years of Radiation Therapy of Unresectable Intrahepatic Cholangiocarinoma: Internal or External? A Systematic Review and Meta-Analysis
Conclusions: Both EBRT and SIRT were safe and effective in treating unresectable iCCA. However, available evidence was highly heterogeneous regarding patient population, limiting fair comparison between 2 radiation modalities. Future high-quality comparative studies are warranted.Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - July 19, 2021 Category: Cancer & Oncology Source Type: research

Baseline Liver Function and Subsequent Outcomes in the Phase 3 REFLECT Study of Patients with Unresectable Hepatocellular Carcinoma
Conclusions: Better liver function at baseline, as measured by ALBI grade or CPS, may be prognostic for better survival outcomes in patients with uHCC undergoing treatment with lenvatinib or sorafenib.Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - July 15, 2021 Category: Cancer & Oncology Source Type: research

Balloon-Occluded Transarterial Chemoembolization: In Which Size Range Does It Perform Best? A Comparison of Its Efficacy versus Conventional Transarterial Chemoembolization, Using Propensity Score Matching
Conclusion: In HCCs of 30 –50 mm, B-TACE should be preferred to cTACE, whereas in smaller nodules (#x3c;30 mm), cTACE can suffice in achieving a good CR rate. The statistically significant lower re-treatment rate of the B-TACE cohort after a single procedure reduced the risk of complications due to multiple TACE, which cou ld worsen the patient prognosis.Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - July 14, 2021 Category: Cancer & Oncology Source Type: research

Ramucirumab for Patients with Intermediate-Stage Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Results from Two Phase 3 Studies (REACH and REACH-2)
Conclusions: Ramucirumab provided a better survival benefit irrespective of BCLC stage and was well tolerated without compromising liver function during treatment.Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - July 12, 2021 Category: Cancer & Oncology Source Type: research

Role of Liver Resection for Hepatocellular Carcinoma with Vascular Invasion: Emerging Evidence from Western Countries
Patients with advanced hepatocellular carcinoma (HCC) with macrovascular invasion, that is, tumor thrombosis in the portal vein or hepatic vein, are generally considered not eligible for liver resection in Western countries, and only systemic therapy is recommended. However, there is a subgroup of patients who can survive long after surgical treatment despite having a very advanced stage of the disease. Some Asian surgical centers and a few Western surgical centers have been using surgery to treat BCLC stage C HCC as long as it is operable, and those centers have reported acceptable outcomes. In this issue ofLiver Cancer, ...
Source: Liver Cancer - July 8, 2021 Category: Cancer & Oncology Source Type: research

Impaired Response to Immunotherapy in Non-Alcoholic Steatohepatitis-Related Hepatocellular Carcinoma?
Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - July 2, 2021 Category: Cancer & Oncology Source Type: research

A Phase 2 Study of Camrelizumab for Advanced Hepatocellular Carcinoma: Two-Year Outcomes and Continued Treatment beyond First RECIST-Defined Progression
Conclusions: With prolonged follow-up, camrelizumab continues to demonstrate the durable response and long survival in pretreated advanced HCC patients with manageable toxicities, especially in those who continued the treatment beyond first RECIST-defined progression.Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - June 30, 2021 Category: Cancer & Oncology Source Type: research

Improved Tumor Response to Lenvatinib Re-Treatment after Failure of Immune Checkpoint Inhibitors in a Patient with Advanced Hepatocellular Carcinoma
Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - June 16, 2021 Category: Cancer & Oncology Source Type: research

Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular Carcinoma
Conclusions: In a real-life Western scenario (mostly in a third-line setting), cabozantinib efficacy and safety data were comparable with those reported in its registration trial. Data regarding the prognostic factors might help in patient selection and design of clinical trials.Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - June 15, 2021 Category: Cancer & Oncology Source Type: research